S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
NASDAQ:RNAC

Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

$17.28
-1.22 (-6.59%)
(As of 04/18/2024 ET)
Today's Range
$16.90
$18.66
50-Day Range
$13.12
$23.61
52-Week Range
$11.66
$42.60
Volume
35,792 shs
Average Volume
41,161 shs
Market Capitalization
$93.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$51.00

Cartesian Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
195.1% Upside
$51.00 Price Target
Short Interest
Healthy
5.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$365,981 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.50) to ($2.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.52 out of 5 stars

Medical Sector

455th out of 918 stocks

Pharmaceutical Preparations Industry

198th out of 402 stocks

RNAC stock logo

About Cartesian Therapeutics Stock (NASDAQ:RNAC)

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

RNAC Stock Price History

RNAC Stock News Headlines

A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
A.I. Pioneer Issues Urgent Warning to Americans
With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics Inc.
See More Headlines
Receive RNAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RNAC
Previous Symbol
NASDAQ:RNAC
Employees
37
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$51.00
High Stock Price Target
$60.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+195.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-219,710,000.00
Net Margins
-845.01%
Pretax Margin
-917.97%

Debt

Sales & Book Value

Annual Sales
$26 million
Book Value
($85.17) per share

Miscellaneous

Free Float
3,710,000
Market Cap
$93.14 million
Optionable
Optionable
Beta
0.57
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Carsten Brunn Ph.D. (Age 52)
    President, CEO & Director
  • Mr. Blaine T. Davis (Age 49)
    Chief Financial Officer
  • Dr. Metin Kurtoglu M.D. (Age 45)
    Ph.D., Chief Operating Officer
  • Yi Zhang Ph.D.
    Senior Director of Technology
  • Dr. Chris Jewell Ph.D. (Age 42)
    Chief Scientific Officer
  • Mr. Matthew Bartholomae J.D.
    General Counsel & Secretary
  • Dr. Milos Miljkovic M.D. (Age 40)
    Ph.D., Chief Medical Officer

RNAC Stock Analysis - Frequently Asked Questions

Should I buy or sell Cartesian Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cartesian Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNAC shares.
View RNAC analyst ratings
or view top-rated stocks.

What is Cartesian Therapeutics' stock price target for 2024?

2 brokerages have issued 1 year price targets for Cartesian Therapeutics' stock. Their RNAC share price targets range from $42.00 to $60.00. On average, they expect the company's share price to reach $51.00 in the next twelve months. This suggests a possible upside of 195.1% from the stock's current price.
View analysts price targets for RNAC
or view top-rated stocks among Wall Street analysts.

How have RNAC shares performed in 2024?

Cartesian Therapeutics' stock was trading at $20.6820 at the beginning of the year. Since then, RNAC stock has decreased by 16.4% and is now trading at $17.28.
View the best growth stocks for 2024 here
.

Are investors shorting Cartesian Therapeutics?

Cartesian Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 293,100 shares, a decline of 96.5% from the March 15th total of 8,300,000 shares. Based on an average daily trading volume, of 32,300 shares, the days-to-cover ratio is currently 9.1 days. Currently, 5.3% of the company's stock are short sold.
View Cartesian Therapeutics' Short Interest
.

When is Cartesian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RNAC earnings forecast
.

How were Cartesian Therapeutics' earnings last quarter?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) announced its quarterly earnings data on Thursday, March, 7th. The company reported ($2.40) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $2.10. The business had revenue of $8.27 million for the quarter. Cartesian Therapeutics had a negative trailing twelve-month return on equity of 58.21% and a negative net margin of 845.01%.

When did Cartesian Therapeutics' stock split?

Cartesian Therapeutics shares reverse split on Friday, April 5th 2024. The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Cartesian Therapeutics?

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNAC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners